drugset / Trial / NCT07226453

Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma

NCT07226453

Non-randomizedSequentialOpen-labelTreatment

Summary

This is a multi-site study of the pharmacodynamic effects and efficacy of metformin in children and young adults with recurrent or progressive Posterior Fossa Group A (PFA) ependymoma.

Timeline

Start
2026-05-05
Primary completion
2028-04-30
Completion
2030-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 1666 mg/m2 Oral